Nuvectis Pharma establishes $60M ATM with Leerink Partners; terminates prior HC Wainwright program

Nuvectis Pharma, Inc.

New ATM agreement with Leerink Partners to sell up to $60M of common stock; 3.0% commission on gross proceeds.
Prior ATM with H.C. Wainwright for up to $40M terminated; ~$18.6M had been sold under that program.
No costs or payments associated with termination of prior ATM.
Sales will be made as at-the-market offerings on Nasdaq subject to customary conditions.
Proceeds from any sales will be used for general corporate purposes as described in the prospectus supplement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.